Hepatorenal Syndrome: A Critical Update

 

 Permissions and Reprints

Abstract

Acute kidney injury (AKI) is common in cirrhotic patients with ascites. Although not the primary etiology of AKI in cirrhotic patients, hepatorenal syndrome (HRS) is a unique form of AKI that develops only in cirrhotic patients. Intense renal vasoconstriction is the hallmark of HRS. Different mechanisms contribute to renal vasoconstriction, with splanchnic vasodilatation and reduced effective blood volume playing a central role. Diagnostic criteria for HRS have been developed and were recently modified, but diagnosing HRS and differentiating it from other causes of AKI in cirrhotic patients continues to be a difficult task in some patients. Given its overall dismal prognosis, strategies to prevent HRS have been developed and proved to be effective in reducing HRS prevalence among cirrhotic patients. Liver transplantation is the ultimate treatment, but more than one treatment modality can be utilized as a bridge to transplantation. This review provides an update on our current understanding of HRS with emphasis on the underlying pathophysiological mechanisms involved, difficulties in diagnosis, and different treatment modalities.

• References

• 1 Kastelan S, Ljubicic N, Kastelan Z, Ostojic R, Uravic M. The role of duplex-Doppler ultrasonography in the diagnosis of renal dysfunction and hepatorenal syndrome in patients with liver cirrhosis. Hepatogastroenterology 2004; 51 (59) 1408-1412
  PubMedGoogle Scholar
• 2 Platt JF, Ellis JH, Rubin JM, Merion RM, Lucey MR. Renal duplex Doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology 1994; 20 (2) 362-369
  CrossrefPubMedGoogle Scholar
• 3 Epstein M, Berk DP, Hollenberg NK , et al. Renal failure in the patient with cirrhosis: the role of active vasoconstriction. Am J Med 1970; 49 (2) 175-185
  CrossrefPubMedGoogle Scholar
• 4 Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8 (5) 1151-1157
  CrossrefPubMedGoogle Scholar
• 5 Martin PY, Ginès P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339 (8) 533-541
  CrossrefPubMedGoogle Scholar
• 6 Mitchell JA, Kohlhaas KL, Sorrentino R, Warner TD, Murad F, Vane JR. Induction by endotoxin of nitric oxide synthase in the rat mesentery: lack of effect on action of vasoconstrictors. Br J Pharmacol 1993; 109 (1) 265-270
  CrossrefPubMedGoogle Scholar
• 7 Laffi G, Foschi M, Masini E , et al. Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation. Hepatology 1995; 22 (6) 1666-1673
  PubMedGoogle Scholar
• 8 Bendtsen F, Schifter S, Henriksen JH. Increased circulating calcitonin gene-related peptide (CGRP) in cirrhosis. J Hepatol 1991; 12 (1) 118-123
  CrossrefPubMedGoogle Scholar
• 9 Guevara M, Ginès P, Jiménez W , et al. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 1998; 114 (2) 336-343
  CrossrefPubMedGoogle Scholar
• 10 Fernández-Rodriguez CM, Prieto J, Quiroga J , et al. Plasma levels of substance P in liver cirrhosis: relationship to the activation of vasopressor systems and urinary sodium excretion. Hepatology 1995; 21 (1) 35-40
  PubMedGoogle Scholar
• 11 De las Heras D, Fernández J, Ginès P , et al. Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology 2003; 38 (2) 452-459
  PubMedGoogle Scholar
• 12 Caraceni P, Viola A, Piscitelli F , et al. Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int 2010; 30 (6) 816-825
  PubMedGoogle Scholar
• 13 Francés R, Zapater P, González-Navajas JM , et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008; 47 (3) 978-985
  CrossrefPubMedGoogle Scholar
• 14 Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009; 50 (3) 604-620
  CrossrefPubMedGoogle Scholar
• 15 Paternostro C, David E, Novo E, Parola M. Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J Gastroenterol 2010; 16 (3) 281-288
  CrossrefPubMedGoogle Scholar
• 16 Møller S, Hobolth L, Winkler C, Bendtsen F, Christensen E. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut 2011; 60 (9) 1254-1259
  CrossrefPubMedGoogle Scholar
• 17 Kiszka-Kanowitz M, Henriksen JH, Møller S, Bendtsen F. Blood volume distribution in patients with cirrhosis: aspects of the dual-head gamma-camera technique. J Hepatol 2001; 35 (5) 605-612
  CrossrefPubMedGoogle Scholar
• 18 Fernandez-Seara J, Prieto J, Quiroga J , et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97 (5) 1304-1312
  PubMedGoogle Scholar
• 19 Maroto A, Ginès P, Arroyo V , et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993; 17 (5) 788-793
  CrossrefPubMedGoogle Scholar
• 20 Guevara M, Bru C, Ginès P , et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology 1998; 28 (1) 39-44
  CrossrefPubMedGoogle Scholar
• 21 Helmy A, Newby DE, Jalan R, Johnston NR, Hayes PC, Webb DJ. Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis. J Hepatol 2003; 38 (1) 44-50
  PubMedGoogle Scholar
• 22 Govindarajan S, Nast CC, Smith WL, Koyle MA, Daskalopoulos G, Zipser RD. Immunohistochemical distribution of renal prostaglandin endoperoxide synthase and prostacyclin synthase: diminished endoperoxide synthase in the hepatorenal syndrome. Hepatology 1987; 7 (4) 654-659
  CrossrefPubMedGoogle Scholar
• 23 Navasa M, Follo A, Filella X , et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998; 27 (5) 1227-1232
  CrossrefPubMedGoogle Scholar
• 24 Boyer TD, Zia P, Reynolds TB. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979; 77 (2) 215-222
  PubMedGoogle Scholar
• 25 Kostreva DR, Castaner A, Kampine JP. Reflex effects of hepatic baroreceptors on renal and cardiac sympathetic nerve activity. Am J Physiol 1980; 238 (5) R390-R394
  PubMedGoogle Scholar
• 26 Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 1995; 122 (11) 816-822
  CrossrefPubMedGoogle Scholar
• 27 Jalan R, Forrest EH, Redhead DN, Dillon JF, Hayes PC. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man?. Gut 1997; 40 (5) 664-670
  CrossrefPubMedGoogle Scholar
• 28 Solis-Herruzo JA, Duran A, Favela V , et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol 1987; 5 (2) 167-173
  CrossrefPubMedGoogle Scholar
• 29 Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006; 43 (2, Suppl 1) S121-S131
  CrossrefPubMedGoogle Scholar
• 30 Trevisani F, Sica G, Mainquà P , et al. Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. Hepatology 1999; 30 (6) 1387-1392
  CrossrefPubMedGoogle Scholar
• 31 Laffi G, Barletta G, La Villa G , et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997; 113 (3) 891-898
  CrossrefPubMedGoogle Scholar
• 32 Ruiz-del-Arbol L, Urman J, Fernández J , et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38 (5) 1210-1218
  CrossrefPubMedGoogle Scholar
• 33 Ruiz-del-Arbol L, Monescillo A, Arocena C , et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42 (2) 439-447
  CrossrefPubMedGoogle Scholar
• 34 Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010; 59 (1) 105-110
  CrossrefPubMedGoogle Scholar
• 35 Ripoll C, Yotti R, Bermejo J, Bañares R. The heart in liver transplantation. J Hepatol 2011; 54 (4) 810-822
  CrossrefPubMedGoogle Scholar
• 36 Naritaka Y, Ogawa K, Shimakawa T , et al. Clinical experience of transjugular intrahepatic portosystemic shunt (TIPS) and its effects on systemic hemodynamics. Hepatogastroenterology 2004; 51 (59) 1470-1472
  PubMedGoogle Scholar
• 37 Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996; 24 (2) 451-459
  CrossrefPubMedGoogle Scholar
• 38 Liu H, Gaskari SA, Lee SS. Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol 2006; 12 (6) 837-842
  PubMedGoogle Scholar
• 39 Saba S, Janczewski AM, Baker LC , et al. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-alpha. Am J Physiol Heart Circ Physiol 2005; 289 (4) H1456-H1467
  CrossrefPubMedGoogle Scholar
• 40 Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000; 6 (4, Suppl 1) S44-S52
  CrossrefPubMedGoogle Scholar
• 41 Pozzi M, Carugo S, Boari G , et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997; 26 (5) 1131-1137
  PubMedGoogle Scholar
• 42 Tsai MH, Peng YS, Chen YC , et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology 2006; 43 (4) 673-681
  CrossrefPubMedGoogle Scholar
• 43 Fernández J, Escorsell A, Zabalza M , et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology 2006; 44 (5) 1288-1295
  CrossrefPubMedGoogle Scholar
• 44 Stadlbauer V, Wright GA, Banaji M , et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 2008; 134 (1) 111-119
  CrossrefPubMedGoogle Scholar
• 45 Ginès A, Fernández-Esparrach G, Monescillo A , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111 (4) 1002-1010
  CrossrefPubMedGoogle Scholar
• 46 Ruiz-del-Arbol L, Monescillo A, Jimenéz W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113 (2) 579-586
  CrossrefPubMedGoogle Scholar
• 47 Follo A, Llovet JM, Navasa M , et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20 (6) 1495-1501
  CrossrefPubMedGoogle Scholar
• 48 Sort P, Navasa M, Arroyo V , et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341 (6) 403-409
  CrossrefPubMedGoogle Scholar
• 49 Fasolato S, Angeli P, Dallagnese L , et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007; 45 (1) 223-229
  CrossrefPubMedGoogle Scholar
• 50 Terra C, Guevara M, Torre A , et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005; 129 (6) 1944-1953
  CrossrefPubMedGoogle Scholar
• 51 Ginès A, Escorsell A, Ginès P , et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105 (1) 229-236
  PubMedGoogle Scholar
• 52 Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119 (6) 1637-1648
  CrossrefPubMedGoogle Scholar
• 53 Cárdenas A, Ginès P, Uriz J , et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 2001; 34 (4 Pt 1) 671-676
  CrossrefPubMedGoogle Scholar
• 54 Laffi G, La Villa G, Pinzani M, Marra F, Gentilini P. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol 1997; 17 (6) 530-548
  PubMedGoogle Scholar
• 55 Planas R, Montoliu S, Ballesté B , et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006; 4 (11) 1385-1394
  CrossrefPubMedGoogle Scholar
• 56 Wong LP, Blackley MP, Andreoni KA, Chin H, Falk RJ, Klemmer PJ. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int 2005; 68 (1) 362-370
  CrossrefPubMedGoogle Scholar
• 57 Montoliu S, Ballesté B, Planas R , et al. Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites. Clin Gastroenterol Hepatol 2010; 8 (7) 616-622, quiz e80
  CrossrefPubMedGoogle Scholar
• 58 Moreau R, Durand F, Poynard T , et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122 (4) 923-930
  CrossrefPubMedGoogle Scholar
• 59 Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56 (9) 1310-1318
  CrossrefPubMedGoogle Scholar
• 60 Arroyo V, Ginès P, Gerbes AL , et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23 (1) 164-176
  CrossrefPubMedGoogle Scholar
• 61 Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol 2002; 97 (8) 2046-2050
  CrossrefPubMedGoogle Scholar
• 62 Colle I, Durand F, Pessione F , et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002; 17 (8) 882-888
  CrossrefPubMedGoogle Scholar
• 63 Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40 (1) 55-64
  CrossrefPubMedGoogle Scholar
• 64 Péron JM, Bureau C, Gonzalez L , et al. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol 2005; 100 (12) 2702-2707
  CrossrefPubMedGoogle Scholar
• 65 Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003; 362 (9398) 1819-1827
  CrossrefPubMedGoogle Scholar
• 66 Wong F, Nadim MK, Kellum JA , et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011; 60 (5) 702-709
  CrossrefPubMedGoogle Scholar
• 67 Salerno F, Cazzaniga M, Merli M , et al. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol 2011; 55 (6) 1241-1248
  CrossrefPubMedGoogle Scholar
• 68 Levin A, Warnock DG, Mehta RL , et al; Acute Kidney Injury Network Working Group. Improving outcomes from acute kidney injury: report of an initiative. Am J Kidney Dis 2007; 50 (1) 1-4
  CrossrefPubMedGoogle Scholar
• 69 Cholongitas E, Senzolo M, Patch D, Shaw S, O’Beirne J, Burroughs AK. Cirrhotics admitted to intensive care unit: the impact of acute renal failure on mortality. Eur J Gastroenterol Hepatol 2009; 21 (7) 744-750
  CrossrefPubMedGoogle Scholar
• 70 Jenq CC, Tsai MH, Tian YC , et al. RIFLE classification can predict short-term prognosis in critically ill cirrhotic patients. Intensive Care Med 2007; 33 (11) 1921-1930
  CrossrefPubMedGoogle Scholar
• 71 Davenport A, Cholongitas E, Xirouchakis E, Burroughs AK. Pitfalls in assessing renal function in patients with cirrhosis—potential inequity for access to treatment of hepatorenal failure and liver transplantation. Nephrol Dial Transplant 2011; 26 (9) 2735-2742
  CrossrefPubMedGoogle Scholar
• 72 Slack A, Yeoman A, Wendon J. Renal dysfunction in chronic liver disease. Crit Care 2010; 14 (2) 214
  CrossrefPubMedGoogle Scholar
• 73 Wadei HM, Geiger XJ, Cortese C , et al. Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy. Am J Transplant 2008; 8 (12) 2618-2626
  CrossrefPubMedGoogle Scholar
• 74 Koppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 1969; 280 (25) 1367-1371
  CrossrefPubMedGoogle Scholar
• 75 Iwatsuki S, Popovtzer MM, Corman JL , et al. Recovery from “hepatorenal syndrome” after orthotopic liver transplantation. N Engl J Med 1973; 289 (22) 1155-1159
  CrossrefPubMedGoogle Scholar
• 76 Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 2005; 21 (2) 478-482
  PubMedGoogle Scholar
• 77 Shusterman B, Mchedishvili G, Rosner MH. Outcomes for hepatorenal syndrome and acute kidney injury in patients undergoing liver transplantation: a single-center experience. Transplant Proc 2007; 39 (5) 1496-1500
  CrossrefPubMedGoogle Scholar
• 78 Xu X, Ling Q, Zhang M , et al. Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience. Transplantation 2009; 87 (10) 1514-1519
  CrossrefPubMedGoogle Scholar
• 79 Rice JP, Skagen C, Said A. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin. Transplantation 2011; 91 (10) 1141-1147
  CrossrefPubMedGoogle Scholar
• 80 García-Compean D, Blanc P, Larrey D , et al. Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. Ann Hepatol 2002; 1 (1) 29-35
  PubMedGoogle Scholar
• 81 Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology 2005; 41 (6) 1211-1219
  CrossrefPubMedGoogle Scholar
• 82 Quinlan GJ, Mumby S, Martin GS, Bernard GR, Gutteridge JM, Evans TW. Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med 2004; 32 (3) 755-759
  CrossrefPubMedGoogle Scholar
• 83 Fernández J, Navasa M, Planas R , et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133 (3) 818-824
  CrossrefPubMedGoogle Scholar
• 84 Arroyo V, Fernandez J. Pathophysiological basis of albumin use in cirrhosis. Ann Hepatol 2011; 10 (Suppl 1) S6-S14
  PubMedGoogle Scholar
• 85 Cade R, Wagemaker H, Vogel S , et al. Hepatorenal syndrome: studies of the effect of vascular volume and intraperitoneal pressure on renal and hepatic function. Am J Med 1987; 82 (3) 427-438
  CrossrefPubMedGoogle Scholar
• 86 Umgelter A, Reindl W, Franzen M, Lenhardt C, Huber W, Schmid RM. Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites. Intensive Care Med 2009; 35 (1) 152-156
  CrossrefPubMedGoogle Scholar
• 87 Umgelter A, Reindl W, Wagner KS , et al. Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial. Crit Care 2008; 12 (1) R4
  CrossrefPubMedGoogle Scholar
• 88 Charlton MR, Wall WJ, Ojo AO , et al; International Liver Transplantation Society Expert Panel. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009; 15 (11) S1-S34
  PubMedGoogle Scholar
• 89 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53 (3) 397-417
  CrossrefPubMedGoogle Scholar
• 90 Ryckwaert F, Virsolvy A, Fort A , et al. Terlipressin, a provasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance. Crit Care Med 2009; 37 (3) 876-881
  CrossrefPubMedGoogle Scholar
• 91 Arroyo V, Fernández J. Management of hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol 2011; 7 (9) 517-526
  PubMedGoogle Scholar
• 92 Ortega R, Ginès P, Uriz J , et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36 (4 Pt 1) 941-948
  CrossrefPubMedGoogle Scholar
• 93 Uriz J, Ginès P, Cárdenas A , et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33 (1) 43-48
  CrossrefPubMedGoogle Scholar
• 94 Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002; 14 (12) 1363-1368
  CrossrefPubMedGoogle Scholar
• 95 Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18 (2) 152-156
  CrossrefPubMedGoogle Scholar
• 96 Narahara Y, Kanazawa H, Taki Y , et al. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol 2009; 24 (11) 1791-1797
  CrossrefPubMedGoogle Scholar
• 97 Nazar A, Pereira GH, Guevara M , et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2010; 51 (1) 219-226
  CrossrefPubMedGoogle Scholar
• 98 Martín-Llahí M, Pépin MN, Guevara M , et al; TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134 (5) 1352-1359
  CrossrefPubMedGoogle Scholar
• 99 Péron JM, Bureau C, Gonzalez L , et al. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol 2005; 100 (12) 2702-2707
  CrossrefPubMedGoogle Scholar
• 100 Fernández J, Monteagudo J, Bargallo X , et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005; 42 (3) 627-634
  CrossrefPubMedGoogle Scholar
• 101 Sanyal AJ, Boyer T, Garcia-Tsao G , et al; Terlipressin Study Group. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134 (5) 1360-1368
  CrossrefPubMedGoogle Scholar
• 102 Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010; 25 (5) 880-885
  CrossrefPubMedGoogle Scholar
• 103 Duvoux C, Zanditenas D, Hézode C , et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002; 36 (2) 374-380
  CrossrefPubMedGoogle Scholar
• 104 Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003; 38 (1) 238-243
  PubMedGoogle Scholar
• 105 Angeli P, Volpin R, Piovan D , et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998; 28 (4) 937-943
  CrossrefPubMedGoogle Scholar
• 106 Singh V, Dhungana SP, Singh B , et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol 2011; Jul 13. [Epub ahead of print]
  PubMedGoogle Scholar
• 107 Angeli P, Volpin R, Gerunda G , et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29 (6) 1690-1697
  CrossrefPubMedGoogle Scholar
• 108 Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 2009; 43 (7) 680-685
  CrossrefPubMedGoogle Scholar
• 109 Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 2005; 20 (9) 1813-1820
  CrossrefPubMedGoogle Scholar
• 110 Dobre M, Demirjian S, Sehgal AR, Navaneethan SD. Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. Int Urol Nephrol 2011; 43 (1) 175-184
  CrossrefPubMedGoogle Scholar
• 111 Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51 (2) 576-584
  CrossrefPubMedGoogle Scholar
• 112 Caraceni P, Santi L, Mirici F , et al. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation. Dig Liver Dis 2011; 43 (3) 242-245
  CrossrefPubMedGoogle Scholar
• 113 Jalan R, Redhead DN, Thomas HW , et al. Mechanisms of changes in renal handling of sodium following transjugular intrahepatic portal systemic stent-shunt (TIPSS). Eur J Gastroenterol Hepatol 1996; 8 (11) 1111-1116
  CrossrefPubMedGoogle Scholar
• 114 Gerbes AL, Gülberg V, Waggershauser T, Holl J, Reiser M. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 1998; 28 (3) 683-688
  CrossrefPubMedGoogle Scholar
• 115 Guevara M, Ginès P, Bandi JC , et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28 (2) 416-422
  CrossrefPubMedGoogle Scholar
• 116 Brensing KA, Textor J, Perz J , et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47 (2) 288-295
  CrossrefPubMedGoogle Scholar
• 117 Rössle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 2010; 59 (7) 988-1000
  CrossrefPubMedGoogle Scholar
• 118 Testino G, Ferro C, Sumberaz A , et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 2003; 50 (54) 1753-1755
  PubMedGoogle Scholar
• 119 Guerrini GP, Pleguezuelo M, Maimone S , et al. Impact of tips preliver transplantation for the outcome posttransplantation. Am J Transplant 2009; 9 (1) 192-200
  CrossrefPubMedGoogle Scholar
• 120 Wilkinson SP, Weston MJ, Parsons V, Williams R. Dialysis in the treatment of renal failure in patients with liver disease. Clin Nephrol 1977; 8 (1) 287-292
  PubMedGoogle Scholar
• 121 Ellis D, Avner ED. Renal failure and dialysis therapy in children with hepatic failure in the perioperative period of orthotopic liver transplantation. Clin Nephrol 1986; 25 (6) 295-303
  PubMedGoogle Scholar
• 122 Keller F, Heinze H, Jochimsen F, Passfall J, Schuppan D, Büttner P. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail 1995; 17 (2) 135-146
  CrossrefPubMedGoogle Scholar
• 123 Davenport A. Renal replacement therapy in the patient with acute brain injury. Am J Kidney Dis 2001; 37 (3) 457-466
  CrossrefPubMedGoogle Scholar
• 124 Davenport A, Will EJ, Davison AM. Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. Kidney Int Suppl 1993; 41: S245-S251
  PubMedGoogle Scholar
• 125 Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 1993; 21 (3) 328-338
  CrossrefPubMedGoogle Scholar
• 126 Detry O, Arkadopoulos N, Ting P , et al. Intracranial pressure during liver transplantation for fulminant hepatic failure. Transplantation 1999; 67 (5) 767-770
  CrossrefPubMedGoogle Scholar
• 127 Witzke O, Baumann M, Patschan D , et al. Which patients benefit from hemodialysis therapy in hepatorenal syndrome?. J Gastroenterol Hepatol 2004; 19 (12) 1369-1373
  CrossrefPubMedGoogle Scholar
• 128 Gonwa TA, Mai ML, Melton LB , et al. Renal replacement therapy and orthotopic liver transplantation: the role of continuous veno-venous hemodialysis. Transplantation 2001; 71 (10) 1424-1428
  CrossrefPubMedGoogle Scholar
• 129 Bellomo R, Teede H, Boyce N. Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Med 1993; 19 (6) 329-332
  CrossrefPubMedGoogle Scholar
• 130 Biancofiore G, Esposito M, Bindi L , et al. Regional filter heparinization for continuous veno-venous hemofiltration in liver transplant recipients. Minerva Anestesiol 2003; 69 (6) 527-534, 534–538
  PubMedGoogle Scholar
• 131 Liu KD, Himmelfarb J, Paganini E , et al. Timing of initiation of dialysis in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 2006; 1 (5) 915-919
  CrossrefPubMedGoogle Scholar
• 132 Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL ; Sepsis Occurrence in Acutely Ill Patients (SOAP) Investigators. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care 2008; 12 (3) R74
  CrossrefPubMedGoogle Scholar
• 133 Palevsky PM, Zhang JH, O’Connor TZ , et al; VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359 (1) 7-20
  CrossrefPubMedGoogle Scholar
• 134 Bellomo R, Cass A, Cole L , et al; RENAL Replacement Therapy Study Investigators. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361 (17) 1627-1638
  CrossrefPubMedGoogle Scholar
• 135 Piccinni P, Dan M, Barbacini S , et al. Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med 2006; 32 (1) 80-86
  CrossrefPubMedGoogle Scholar
• 136 Mitzner SR, Stange J, Klammt S , et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6 (3) 277-286
  CrossrefPubMedGoogle Scholar
• 137 Faubion WA, Guicciardi ME, Miyoshi H , et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 1999; 103 (1) 137-145
  CrossrefPubMedGoogle Scholar
• 138 Bomzon A, Holt S, Moore K. Bile acids, oxidative stress, and renal function in biliary obstruction. Semin Nephrol 1997; 17 (6) 549-562
  PubMedGoogle Scholar
• 139 Mitzner SR, Klammt S, Peszynski P , et al. Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther Apher 2001; 5 (5) 417-422
  CrossrefPubMedGoogle Scholar
• 140 Oppert M, Rademacher S, Petrasch K, Jörres A. Extracorporeal liver support therapy with Prometheus in patients with liver failure in the intensive care unit. Ther Apher Dial 2009; 13 (5) 426-430
  CrossrefPubMedGoogle Scholar
• 141 Townsend DR, Bagshaw SM, Jacka MJ, Bigam D, Cave D, Gibney RT. Intraoperative renal support during liver transplantation. Liver Transpl 2009; 15 (1) 73-78
  CrossrefPubMedGoogle Scholar
• 142 Navasa M, Feu F, García-Pagán JC , et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology 1993; 17 (3) 355-360
  CrossrefPubMedGoogle Scholar
• 143 Piscaglia F, Zironi G, Gaiani S , et al. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. Hepatology 1999; 30 (1) 58-64
  CrossrefPubMedGoogle Scholar
• 144 Ruiz R, Kunitake H, Wilkinson AH , et al. Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg 2006; 141 (8) 735-741 , discussion 741–742
  CrossrefPubMedGoogle Scholar
• 145 Jeyarajah DR, Gonwa TA, McBride M , et al. Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant. Transplantation 1997; 64 (12) 1760-1765
  CrossrefPubMedGoogle Scholar
• 146 Eason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant 2008; 8 (11) 2243-2251
  CrossrefPubMedGoogle Scholar
• 147 Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003; 9 (7) 741-747
  CrossrefPubMedGoogle Scholar
• 148 Gonwa TA, Mai ML, Melton LB , et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72 (12) 1934-1939
  CrossrefPubMedGoogle Scholar
• 149 Lee JP, Heo NJ, Joo KW , et al. Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function. Nephrol Dial Transplant 2010; 25 (8) 2772-2785
  CrossrefPubMedGoogle Scholar
• 150 Ruiz R, Barri YM, Jennings LW , et al. Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT). Liver Transpl 2007; 13 (6) 838-843
  CrossrefPubMedGoogle Scholar
• 151 Gonwa TA, McBride MA, Mai ML, Wadei HM. Kidney transplantation after previous liver transplantation: analysis of the organ procurement transplant network database. Transplantation 2011; 92 (1) 31-35
  CrossrefPubMedGoogle Scholar
• 152 Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59 (3) 361-365
  PubMedGoogle Scholar
• 153 Restuccia T, Ortega R, Guevara M , et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a case-control study. J Hepatol 2004; 40 (1) 140-146
  PubMedGoogle Scholar
• 154 Arroyo V, Fernandez J, Ginès P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008; 28 (1) 81-95
  Article in Thieme ConnectPubMedGoogle Scholar
• 155 Davenport A. Management of acute kidney injury in liver disease. Contrib Nephrol 2010; 165: 197-205
  PubMedGoogle Scholar